

CITATION REPORT

List of articles citing

**Chronic sildenafil treatment inhibits
monocrotaline-induced pulmonary hypertension in rats**

DOI: 10.1164/rccm.200302-282oc

**American Journal of Respiratory and Critical Care
Medicine, 2004, 169, 39-45.**

Source: <https://exaly.com/paper-pdf/36538207/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
221	Sildenafil for pulmonary arterial hypertension: still waiting for evidence. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 169, 6-7	10.2	17
220	Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. 2004 , 1, 183-9		24
219	Endogenous production of ghrelin and beneficial effects of its exogenous administration in monocrotaline-induced pulmonary hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004 , 287, H2885-90	5.2	55
218	A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 169, 34-8	10.2	90
217	Sildenafil. 2004 ,		
216	Aortic smooth muscle relaxants KMUP-3 and KMUP-4, two nitrophenylpiperazine derivatives of xanthine, display cGMP-enhancing activity: roles of endothelium, phosphodiesterase, and K ⁺ channel. 2005 , 46, 600-8		12
215	Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. 2005 , 69, 461-5		45
214	Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. 2005 , 60, 107-12		165
213	Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. 2005 , 146, 1010-8		120
212	Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. 2005 , 510, 87-96		16
211	Sildenafil and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets. 2005 , 40, 72-80		13
210	Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus. 2005 , 288, L1193-200		18
209	Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. 2005 , 19, 1175-7		144
208	Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 358-63	10.2	55
207	Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil?. 2005 , 94, 774-7		24
206	Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 750-6	10.2	152
205	Interstitial lung disease, lung cancer, lung transplantation, pulmonary vascular disorders, and sleep-disordered breathing in AJRCCM in 2004. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 171, 675-85	10.2	2

204	Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension. 2005 , 67, 251-84	8
203	Phosphodiesterase type 5 and high altitude pulmonary hypertension. 2005 , 60, 683-7	66
202	Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. 2005 , 112, 423-31	212
201	Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 105-13	10.2 266
200	Sildenafil citrate therapy for pulmonary arterial hypertension. 2005 , 353, 2148-57	1843
199	Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. 2005 , 5, 245-50	40
198	New therapeutic agents for pulmonary vascular disease. 2005 , 6, 285-91	19
197	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. 2005 , 6, 128	29
196	Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. 2006 , 5, 271-82	8
195	Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. 2006 , 4, 293-300	41
194	Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. 2006 , 20, 722-35	22
193	Sildenafil citrate for the treatment of pulmonary arterial hypertension. 2006 , 7, 825-8	7
192	Hypoxia and dehydroepiandrosterone in old age: a mouse survival study. 2006 , 7, 144	18
191	Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb. 2006 , 81, 935-42	19
190	Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. 2006 , 70, 1208-15	38
189	Effects of sildenafil on hypoxic pulmonary vascular function in dogs. 2006 , 101, 1085-90	28
188	Vasoactive mediators and pulmonary hypertension after cigarette smoke exposure in the guinea pig. 2006 , 100, 672-8	59
187	Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. 2006 , 100, 2031-40	104

186	Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. 2006 , 97, 625-33	98
185	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702	366
184	Measuring satisfaction in family members of critically ill cancer patients in Brazil. 2006 , 32, 124-8	23
183	How valid are animal models to evaluate treatments for pulmonary hypertension?. 2006 , 373, 391-400	58
182	Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. 2006 , 3, 84-94; discussion 94-5	28
181	Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. 2006 , 15, 327-30	2
180	[Reverse remodeling -- paradigm shift in the treatment of pulmonary hypertension]. 2006 , 131, 871-4	2
179	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. 2007 , 19, 139-48	45
178	Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension. 2007 , 115, 2957-68	43
177	Early changes in rat hearts with developing pulmonary arterial hypertension can be detected with three-dimensional electrocardiography. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 293, H1300-7	5.2 34
176	Modulation of ion channels in pulmonary arterial hypertension. 2007 , 13, 2443-55	38
175	Rodent models of PAH: are we there yet?. 2007 , 293, L580-2	40
174	Expert opinion on available options treating pulmonary arterial hypertension. 2007 , 8, 2247-65	30
173	PDE5 inhibitors beyond erectile dysfunction. 2007 , 19, 533-43	57
172	The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. 2007 , 105, 1034-41, table of contents	33
171	Treatment of chronic mountain sickness: critical reappraisal of an old problem. 2007 , 158, 251-65	43
170	The nitric oxide/cGMP signaling pathway in pulmonary hypertension. 2007 , 28, 143-67, ix	66
169	[Animal models of pulmonary arterial hypertension]. 2007 , 24, 481-96	19

168	Traitement médical de l'hypertension artérielle pulmonaire. 2007 , 56, S123-S136	
167	Therapy of pulmonary hypertension in neonates and infants. 2007 , 114, 318-26	9
166	Failure to achieve glycemic control despite intensive insulin therapy in a medical ICU: incidence and influence on ICU mortality. 2007 , 33, 814-821	59
165	Novel approach with intratracheal administration of microgelatin hydrogel microspheres incorporating basic fibroblast growth factor for rescue of rats with monocrotaline-induced pulmonary hypertension. 2008 , 136, 1250-6	8
164	Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil. 2008 , 80, 249-52	33
163	Pulmonary Hypertension. 2008 ,	3
162	Therapeutic advances in pulmonary arterial hypertension. 2008 , 2, 249-65	30
161	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. 2008 , 32, 198-209	101
160	Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. 2008 , 31, 599-610	26
159	Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca ²⁺ entry. 2008 , 108, 71-8	33
158	The Protective Effect of Simvastatin on Monocrotaline-Induced Pulmonary Hypertension in Rats. 2008 , 38, 313	3
157	Present and Prospective Pharmacotherapies in Pulmonary Arterial Hypertension. 2009 , 1, CMT.S2108	
156	Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent?. 2009 , 82, 4-6	2
155	Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. 2009 , 82, 30-9	56
154	Vasoproliferation and antiproliferative treatment options in pulmonary arterial hypertension. 2009 , 4, 142-9	3
153	PDE5 inhibitors in non-urolological conditions. 2009 , 15, 3521-39	24
152	The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. 2009 , 40, 683-91	80
151	Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 297, H200-7	5.2 33

150	Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 297, H1606-16	5.2	90
149	Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. 2009 , 33, 861-70		39
148	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. 2009 , 26, 813-25		75
147	Endothelin receptor antagonists in preclinical models of pulmonary hypertension. 2009 , 39 Suppl 2, 3-13		8
146	Cyclic GMP-hydrolyzing phosphodiesterases. 2009 , 367-408		28
145	Inhibition of SOC/Ca ²⁺ /NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells. 2009 , 10, 123		56
144	Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. 2009 , 10, 30		90
143	cGMP: Generators, Effectors and Therapeutic Implications. 2009 ,		13
142	Sildenafil® protective effect against cardiac hypertrophy. 2009 , 2, 323-7		2
141	Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. 2009 , 111, 235-43		40
140	Is there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function?. 2009 , 15, 3506-20		9
139	Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling. 2010 , 55, 574-84		43
138	Pulmonary hemodynamic response to acute combination and monotherapy with sildenafil and brain natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension. 2010 , 339, 55-9		7
137	Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension. 2010 , 25, 313-8		7
136	BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats. 2010 , 647, 147-54		20
135	Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy. 2010 , 8, 88		34
134	Downregulation of oxytocin receptors in right ventricle of rats with monocrotaline-induced pulmonary hypertension. 2010 , 200, 147-58		14
133	Rapid Quantification of Myocardial Fibrosis: A New Macro-Based Automated Analysis. 2010 , 33, 257-269		22

132	Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension. 2010 , 40, 659-64	9
131	Gene expression of endothelin-1 and endothelin receptor a on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. 2010 , 40, 459-64	18
130	Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. 2010 , 51, 272-6	37
129	Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. 2010 , 332, 455-62	60
128	Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. 2010 , 36, 808-18	43
127	Tadalafil for the treatment of pulmonary arterial hypertension. 2010 , 11, 127-32	27
126	Novel approaches to treat experimental pulmonary arterial hypertension: a review. 2010 , 2010, 702836	23
125	Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. 2010 , 36, 800-7	73
124	L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats. 2010 , 298, E1131-9	38
123	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. 2010 , 19, 1427-37	61
122	Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. 2010 , 23, 456-64	25
121	The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. 2010 , 23, 235-56	220
120	The effect of sildenafil citrate administration on selected physiological parameters of exercising Thoroughbred horses. 2010 , 42, 606-12	6
119	Targeting cancer with phosphodiesterase inhibitors. 2010 , 19, 117-31	105
118	Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial. 2011 , 12, 207-14	27
117	Riociguat for the treatment of pulmonary hypertension. 2011 , 20, 567-76	69
116	Tadalafil for the treatment of pulmonary arterial hypertension. 2011 , 5, 315-28	7
115	Sildenafil up-regulates Kv1.5 mRNA expression in rats with pulmonary hypertension. 2011 , 5, 2094-2099	

114	Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. 2011 , 6, e18136	30
113	Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models. 2011 , 6, e19922	9
112	Chronic vardenafil treatment improves erectile function via structural maintenance of penile corpora cavernosa in rats with acute arteriogenic erectile dysfunction. 2011 , 8, 705-11	19
111	Rapid quantification of myocardial fibrosis: a new macro-based automated analysis. 2011 , 34, 343-54	98
110	VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. 2011 , 12, 141	30
109	Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. 2012 , 302, L56-67	33
108	Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension. 2012 , 302, L875-90	20
107	A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. 2012 , 302, L977-91	129
106	Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension. 2012 , 59, 355-62	73
105	The monocrotaline model of pulmonary hypertension in perspective. 2012 , 302, L363-9	264
104	Enhanced protection against pulmonary hypertension with sildenafil and endothelial progenitor cell in rats. 2012 , 162, 45-58	27
103	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. 2012 , 7, e43433	89
102	Comparison of two experimental models of pulmonary hypertension. 2012 , 38, 452-60	5
101	Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not. 2012 , 349, 145-53	11
100	Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle. 2012 , 56, 64-73	42
99	Effects of everolimus in combination with sildenafil in monocrotaline-induced pulmonary hypertension in rats. 2012 , 12, 46-55	2
98	Reactive oxygen species in pulmonary vascular remodeling. 2013 , 3, 1011-34	103
97	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. 2013 , 9, 1193-205	19

96	Pulmonary arterial hypertension. 2013 , 8, 97	168
95	Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. 2013 , 19, 2213-31	57
94	Is N-acetyl cysteine protective against monocrotaline-induced toxicity?. 2013 , 32, 47-54	2
93	Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil. 2013 , 186, 61-4	6
92	Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. 2013 , 58, 211-8	16
91	Sildenafil improves long-term effect of endothelial progenitor cell-based treatment for monocrotaline-induced rat pulmonary arterial hypertension. 2013 , 15, 209-23	22
90	Assessment of the endothelial functions in monocrotaline-induced pulmonary hypertension. 2013 , 35, 220-7	8
89	Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. 2013 , 34, 811-24	4
88	Antioxidant effects of phosphodiesterase-5 inhibitors: reply. 2013 , 100, 170-1	
87	The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition. 2013 , 62, 167-73	13
86	A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?. 2013 , 3, 739-56	104
85	The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload. 2013 , 98, 1274-8	9
84	Therapeutic effect of eNOS-transfected endothelial progenitor cells on hemodynamic pulmonary arterial hypertension. 2013 , 36, 414-21	15
83	Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension. 2013 , 8, e63504	15
82	Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt. 2014 , 9, e104890	31
81	Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats. 2014 , 40, 421-4	13
80	Effects of chronic exposure to cigarette smoke on canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. 2014 , 306, C364-73	27
79	PKG-1 β ucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension. 2014 , 307, L537-44	14

78	Determination of the effects of pulmonary arterial hypertension and therapy on the cardiovascular system of rats by impedance cardiography. 2014 , 55, 498-506	6
77	Acute effects of levosimendan in experimental models of right ventricular hypertrophy and failure. 2014 , 4, 511-9	16
76	Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement. 2014 , 46, 281-5	10
75	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90	10
74	Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model. 2014 , 30, 267-78	13
73	Reversal of echocardiographic right-sided heart pathology in a dog with severe pulmonary hypertension: a case report. 2015 , 6, 211-218	1
72	Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children. 2015 , 14, 633-42	3
71	Diagnosis and Management of Pulmonary Hypertension. 2015 ,	
70	Poly (ADP-ribose) polymerase-1: an emerging target in right ventricle dysfunction associated with pulmonary hypertension. 2015 , 30, 66-79	14
69	Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. 2015 , 5, 305-12	13
68	Sildenafil in a cigarette smoke-induced model of COPD in the guinea-pig. 2015 , 46, 346-54	14
67	Withania somnifera shows a protective effect in monocrotaline-induced pulmonary hypertension. 2015 , 53, 147-57	14
66	Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia. 2016 , 71, 517-25	33
65	Oxidative Stress Influence in the Development of Pulmonary Arterial Hypertension. 2016 , 213-226	
64	Calcilytics enhance sildenafil-induced antiproliferation in idiopathic pulmonary arterial hypertension. 2016 , 784, 15-21	13
63	Klotho and Pulmonary Hypertension: Spinning a Yarn or the Thread of Life?. 2016 , 68, 1106-1107	
62	Comparison of preventive effect of sildenafil and therapeutic effect of sildenafil treatment in rats with monocrotaline-induced pulmonary arterial hypertension. 2016 , 78, 1607-1610	2
61	A study on the involvement of GABA-transaminase in MCT induced pulmonary hypertension. 2016 , 36, 10-21	3

60	Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro. 2017 , 810, 44-50	14
59	Challenges in the development of chronic pulmonary hypertension models in large animals. 2017 , 7, 156-166	11
58	Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. 2017 , 165, 277-292	18
57	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 373-385	10.2 57
56	Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugden-Hypoxia Rat Model. 2018 , 364, 258-274	15
55	Effects of paclitaxel intervention on pulmonary vascular remodeling in rats with pulmonary hypertension. 2019 , 17, 1163-1170	2
54	The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension. 2018 , 9, 1167	17
53	Compensated right ventricular function of the onset of pulmonary hypertension in a rat model depends on chamber remodeling and contractile augmentation. 2018 , 8, 2045894018800439	6
52	Eulophia macrobulbon extract relaxes rat isolated pulmonary artery and protects against monocrotaline-induced pulmonary arterial hypertension. 2018 , 50, 157-165	13
51	Effects of the FGF receptor-1 inhibitor, infgratinib, with or without sildenafil, in experimental pulmonary arterial hypertension. 2019 , 176, 4462-4473	6
50	Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4 Weeks of Chronic Hypoxia. 2019 , 33, 407-414	6
49	Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model. 2019 , 42, 951-965	5
48	Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. 2019 , 62, 4979-4990	13
47	Pharmacological characterization of a highly selective Rho kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension. 2019 , 850, 126-134	8
46	Targeted Delivery of Sildenafil for Inhibiting Pulmonary Vascular Remodeling. 2019 , 73, 703-711	17
45	Characteristics of Pulmonary Vascular Remodeling in a Porcine Model of Shunt-Associated Pulmonary Arterial Hypertension. 2020 , 41, 669-676	1
44	Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension. 2020 , 887, 173438	4
43	Perillyle alcohol and Quercetin ameliorate monocrotaline-induced pulmonary artery hypertension in rats through PARP1-mediated miR-204 down-regulation and its downstream pathway. 2020 , 20, 218	7

42	A novel rat model of pulmonary hypertension induced by mono treatment with SU5416. 2020 , 43, 754-764	2
41	Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. 2020 , 10, 2339-2347	9
40	Therapeutic sildenafil inhibits pulmonary damage induced by cigarette smoke exposure and bacterial inhalation in rats. 2020 , 58, 116-123	5
39	Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects. 2021 , 43, 270-280	6
38	Experimental Models. 2021 , 27-52	
37	Animal models of pulmonary hypertension: Getting to the heart of the problem. 2021 ,	3
36	Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates. 2021 , 28, 2418-2437	2
35	Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension. 2021 , 26, 665-676	3
34	Quercetin, Perillyl Alcohol, and Berberine Ameliorate Right Ventricular Disorders in Experimental Pulmonary Arterial Hypertension: Effects on miR-204, miR-27a, Fibrotic, Apoptotic, and Inflammatory Factors. 2021 , 77, 777-786	5
33	Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension. 2021 , 320, R835-R850	1
32	Modulation of cGMP Synthesis and Metabolism. 2015 , 355-375	1
31	Reversal of experimental pulmonary hypertension by PDGF inhibition. 2005 , 115, 2811-21	764
30	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. 2015 , 10, e0129327	24
29	Aberrant cGMP signaling persists during recovery in mice with oxygen-induced pulmonary hypertension. 2017 , 12, e0180957	8
28	Therapeutic benefits of intravenous cardiosphere-derived cell therapy in rats with pulmonary hypertension. 2017 , 12, e0183557	12
27	Sildenafil in the treatment of pulmonary hypertension. 2006 , 2, 411-22	88
26	An inhibitory effect of tumor necrosis factor-alpha antagonist to gene expression in monocrotaline-induced pulmonary hypertensive rats model. <i>Korean Journal of Pediatrics</i> , 2013 , 56, 116-244	4
25	NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. 2004 , 163-168	

24	Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. 2004 , 129-142		
23	Role of PDE5 in Migraine. 2006 ,		
22	Lungengefäßkrankungen. 2008 , 433-528		
21	Effect of endothelin receptor blockade on monocrotaline-induced pulmonary hypertension in rats. <i>Korean Journal of Pediatrics</i> , 2009 , 52, 689	2.4	6
20	The Influence of the Major Vasoactive Mediators Relevant to the Pathogenesis of Pulmonary Hypertension. 2011 , 117-133		
19	Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. 2011 , 1477-1485		
18	Experimental Models. 2014 , 45-67		
17	Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus. <i>Anatolian Journal of Cardiology</i> , 2017 , 17, 8-17	0.8	6
16	Effect of sildenafil citrate on brain central fatigue after exhaustive swimming exercise in rats. <i>Journal of Exercise Rehabilitation</i> , 2019 , 15, 651-656	1.8	2
15	PDE5 Inhibitors and the cGMP Pathway in Pulmonary Arterial Hypertension. 2008 , 305-319		
14	Plexiform Lesions in an Experimental Model of Monocrotalin-Induced Pulmonary Arterial Hypertension. <i>Arquivos Brasileiros De Cardiologia</i> , 2020 , 115, 480-490	1.2	3
13	Plexiform Lesions in Pulmonary Arterial Hypertension: Are we Getting Closer to Manage with More Patience and Rigor?. <i>Arquivos Brasileiros De Cardiologia</i> , 2020 , 115, 491-492	1.2	1
12	Hemodynamic and histologic characterization of a swine (<i>Sus scrofa domestica</i>) model of chronic pulmonary arterial hypertension. <i>Comparative Medicine</i> , 2011 , 61, 258-62	1.6	6
11	Sildenafil Reduces Inflammation and Prevents Pulmonary Arterial Remodeling of the Monocrotaline - induced Disease in the Wistar Rats. <i>Médica</i> , 2012 , 7, 109-16		9
10	Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats. <i>BMC Pulmonary Medicine</i> , 2021 , 21, 377	3.5	0
9	Perillyl alcohol and quercetin modulate the expression of non-coding RNAs MIAT, H19, miR-29a, and miR-33a in pulmonary artery hypertension in rats.. <i>Non-coding RNA Research</i> , 2022 , 7, 27-33	6	0
8	The Effects of Ginsenoside Compound K on Pulmonary Arterial Hypertension Rats: Suppression of Vascular Remodeling and Inhibiting NF- κ B/NLRP3 Inflammasome Signalling. <i>SSRN Electronic Journal</i> ,	1	
7	Mechanisms of Pulmonary Vascular Dysfunction in Pulmonary Hypertension and Implications for Novel Therapies.. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022 ,	5.2	1

6	Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.. <i>BMC Pulmonary Medicine</i> , 2022 , 22, 142	3.5	0
5	SIRT 1 Activator Loaded Inhaled Antiangiogenic Liposomal Formulation Development for Pulmonary Hypertension. <i>AAPS PharmSciTech</i> , 2022 , 23,	3.9	0
4	PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?.		1
3	The role of lung macrophages in chronic obstructive pulmonary disease. 2022 , 107035		1
2	Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model. 2023 , 24, 2391		0
1	Right ventricular failure in pulmonary hypertension: recent insights from experimental models.		0